REGAFFAIRS AI
Guide · 2026-11-08 · 6 min

Food for special medical purposes under EU, UK and US rules

Food for special medical purposes meets patients' dietary needs under medical supervision. Learn EU classification, labelling and notification rules.

Food for special medical purposes (FSMP) is specially processed or formulated food for the dietary management of patients, including infants, under medical supervision. Under EU Regulation 609/2013, Article 2(2)(g), it is for exclusive or partial feeding where modifying the normal diet alone cannot meet those needs.

EU rules set specific composition, labelling and notification duties, while US "medical foods" have a separate legal definition. Assess the product and label against each market's rules rather than assuming the categories are interchangeable. The relevant starting points are Commission Delegated Regulation (EU) 2016/128 and the US statutory definition.

What qualifies as food for special medical purposes?

Intended patients may have a limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food, certain nutrients or metabolites, or they may have other medically determined nutrient requirements. In either case, normal dietary modification alone must be insufficient for their dietary management. These are conditions of the statutory definition, not optional positioning choices.

But a doctor's recommendation alone doesn't establish FSMP status. Naming a disease on the pack doesn't either. The operator needs objective evidence that the product meets the definition, as explained in the Commission's classification Notice, paragraphs 75-76.

The Notice includes supplements and fortified foods within normal dietary modification, and it calls for a practical, individual assessment rather than proof of absolute impossibility. This is interpretative guidance, not binding legislation or a universal clinical-trial checklist. Use it to assess the intended patients' needs and why ordinary dietary options cannot meet them. See paragraphs 61 and 65-70.

Complete and incomplete formulations

Article 2 of Regulation 2016/128 separates FSMPs into three composition categories:

  • Nutritionally complete food with a standard formulation, potentially suitable as the sole source of nourishment when used as instructed.
  • Nutritionally complete food adapted to a disease, disorder or medical condition, also potentially suitable as the sole source.
  • Nutritionally incomplete food with a standard or adapted formulation, which is unsuitable as the sole source.

Complete products may also provide partial feeding. These categories describe nutritional completeness, not separate approval routes. Sole-source suitability depends on the formulation and its instructed use. Don't present an incomplete formulation as a patient's only food source. All three categories require sound medical and nutritional principles. Generally accepted scientific data must demonstrate safe, beneficial and effective use in meeting the intended patients' specific nutritional requirements. This concerns nutritional suitability, not proof that the food treats the disease. The same regulation's Annex I separates infant and other FSMP composition requirements.

EU labelling requirements

The English legal name is "Food for special medical purposes" (Article 4 and Annex IV). Use that name on the label. General food-information rules still apply unless the specific FSMP rules provide otherwise. Article 5 of Regulation 2016/128 requires these additional particulars:

Label informationWhen required
Statement that the product must be used under medical supervisionAlways
Whether it is suitable as the sole source of nourishmentAlways
Intended age groupWhere appropriate
Hazard if consumed by people without the intended conditionWhere appropriate
"For the dietary management of …", naming the disease, disorder or conditionAlways
Precautions and contraindicationsWhere appropriate
Properties making it useful, relevant formulation changes and their rationaleAlways
Warning that it is not for parenteral useWhere appropriate
Preparation, use and storage-after-opening instructionsAs appropriate

The statements in the first four rows, where the label uses them, must be preceded by "important notice" or equivalent wording. Conditional warnings need a product-specific assessment, so don't treat every warning as compulsory for every formulation. The table summarises Article 5, rather than replacing a full label review.

An expanded nutrition declaration is required regardless of pack size. It includes Annex I vitamins and minerals present, relevant nutrient components and the protein's source and nature. Osmolality or osmolarity must appear where appropriate. The specified energy and nutrient information cannot use percentages of reference intakes. Mandatory nutrition-declaration information must not be repeated elsewhere on the label. These rules appear in Article 6.

Dietary management is not a health claim

Nutrition and health claims are prohibited on FSMPs under Article 7. The required dietary-management statement and formulation explanation do not remove that ban.

Article 9(5) of Regulation 609/2013 also prohibits misleading information and claims that attribute or imply prevention, treatment or cure of human disease. Describing a food's nutritional role doesn't make it a medicine. Infant FSMPs need a separate review of Article 8's restrictions, including imagery, differentiation from ordinary formula, advertising, retail promotion and samples.

Notification is not product approval

The operator normally notifies the competent authority of each EU Member State where the product is marketed. Article 9 of Regulation 2016/128 requires a model label and other compliance information that the authority reasonably requests. A Member State may exempt operators through a national system that guarantees efficient official monitoring.

There is no single EU-wide filing. Use each destination authority's process and check whether a national exemption applies. The Commission Notice, paragraph 19, states that EU law does not require authorisation to place FSMPs on the market. Operators remain responsible for classification and compliance. That position doesn't remove unrelated ingredient or novel-food requirements.

Great Britain and Northern Ireland need separate checks

The DHSC nutrition legislation information sheet distinguishes Great Britain's domestic legislation from applicable EU legislation in Northern Ireland. Check the GB permitted-substances list for GB and the EU Union list for NI. Later EU amendments do not automatically amend GB law.

The DHSC information sheet, section 5.6, sets out the notification responsibilities. DHSC centrally coordinates notification forms for England, Scotland and Wales. The Food Standards Agency is the designated competent authority in Northern Ireland. Use the notification forms collection and the email addresses in the forms. The collection says postal notifications cannot be received.

DHSC says it cannot authorise individual products' composition or labelling. Notification is not an endorsement. Check the destination-market route rather than treating the UK as one filing territory. That split is easy to miss. The route is set out in the DHSC information sheet.

How US medical foods differ

US law defines a medical food as food formulated to be consumed or administered enterally under a physician's supervision, and intended for the specific dietary management of a disease or condition with distinctive nutritional requirements established by medical evaluation and recognised scientific principles. This is the US statutory test, not an alternative name for any EU FSMP.

For the nutrition-labelling exemption, 21 CFR 101.9(j)(8) sets further qualifying conditions. These include specially formulated or processed oral or tube-fed food, needs that normal dietary modification cannot manage, specifically modified nutritional support and active, ongoing medical supervision.

Qualifying medical foods are exempt from the standard Nutrition Facts requirement under that provision. They're not exempt from all labelling or food law. The FDA states that medical foods do not undergo premarket approval, while identifying duties such as manufacturing practices and food-facility registration. Don't describe them as FDA-approved. EU notification and the absence of US premarket approval are different procedural concepts.

"Medical food supplement" can also confuse classification. Dietary supplements have a separate statutory definition, including an intent to supplement the diet and labelling as a dietary supplement. Similar ingredients don't make the categories interchangeable. Do not treat "food for special dietary use" as another name for a medical food or an FSMP. Start with intended use and the applicable legal test, not the marketing term "medical nutrition".

Before launch, check intended use, supporting evidence, label wording and destination-market notification obligations. RegAffairs AI's answer on FSMP classification and US medical foods links the regulatory sources behind this distinction.

Related guides